XML 54 R42.htm IDEA: XBRL DOCUMENT
v3.22.1

Related Parties - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Mar. 31, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Jan. 31, 2021
Related Party Transaction [Line Items] |  |  |  |
Research and development expense |  | $ 20,071,000 | $ 32,774,000 |
Pfizer License Agreement |  |  |  |
Related Party Transaction [Line Items] |  |  |  |
Research and development expense |  |  | 25,000,000.0 |
Upfront payments |  |  | $ 5,000,000.0 |
Series B Convertible Preferred Stock | Pfizer License Agreement |  |  |  |
Related Party Transaction [Line Items] |  |  |  |
Issuance of convertible preferred stock shares |  |  | 12,152,145 |
Issuance of convertible preferred stock value | $ 20,000,000.0 |  | $ 20,000,000.0 | $ 20,000,000.0
Voxall |  |  |  |
Related Party Transaction [Line Items] |  |  |  |
Contributed amount to joint venture | $ 50,000 | $ 0 |  |

X
- Definition Contributed amount to joint venture by each entity. + References No definition available. + Details
Name: | pyxs_ContributedAmountToJointVentureByEachEntity
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Convertible preferred stock shares issued value. + References No definition available. + Details
Name: | pyxs_ConvertiblePreferredStockSharesIssuedValue
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Issuance of convertible preferred stock shares. + References No definition available. + Details
Name: | pyxs_IssuanceOfConvertiblePreferredStockShares
Namespace Prefix: | pyxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | pyxs_UpfrontPayments
Namespace Prefix: | pyxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TransactionTypeAxis=pyxs_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=pyxs_SeriesBConvertiblePreferredStocksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=pyxs_VoxallMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |